drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T)
drug_description
An autologous anti-BCMA chimeric antigen receptor T-cell (CAR T) therapy generated by ex vivo retroviral transduction and infused fresh; CAR T cells bind BCMA (TNFRSF17) on clonal plasma cells and mediate targeted cytotoxicity to reduce amyloidogenic free light chains.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered ex vivo via retroviral transduction to express a BCMA (TNFRSF17)-targeted chimeric antigen receptor; upon binding BCMA on clonal plasma cells, the CAR activates T-cell effector functions to mediate targeted cytotoxicity, eliminating light chain–producing cells and reducing amyloidogenic free light chains.
drug_name
NXC-201 (HBI0101)
nct_id_drug_ref
NCT06097832